[
  {"nct_id":"NCT06000001","title":"Phase 3 retatrutide obesity (Korean site)","sponsor":"Lilly","country":"Korea","drug":"retatrutide","phase":"3","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000002","title":"Phase 2 cagrilintide+semaglutide obesity","sponsor":"Novo Nordisk","country":"Korea","drug":"cagrilintide+semaglutide","phase":"2","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000003","title":"Phase 3 resmetirom MASH long-term","sponsor":"Madrigal","country":"Korea","drug":"resmetirom","phase":"3","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000004","title":"Phase 2 amycretin oral obesity","sponsor":"Novo Nordisk","country":"Korea","drug":"amycretin","phase":"2","recruitment_status":"not yet recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000005","title":"Phase 3 orforglipron T2DM/obesity","sponsor":"Lilly","country":"Korea","drug":"orforglipron","phase":"3","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000006","title":"Phase 2 finerenone obesity-CKD","sponsor":"Bayer","country":"Korea","drug":"finerenone","phase":"2","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000007","title":"Phase 2b ASGR1 antagonist NASH","sponsor":"Bayer","country":"Korea","drug":"ASGR1-antagonist","phase":"2","recruitment_status":"not yet recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000008","title":"Phase 3 tirzepatide MASH","sponsor":"Lilly","country":"Korea","drug":"tirzepatide","phase":"3","recruitment_status":"recruiting","sub_investigator_open":false},
  {"nct_id":"NCT06000009","title":"Phase 2 danuglipron oral GLP-1","sponsor":"Pfizer","country":"Korea","drug":"danuglipron","phase":"2","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000010","title":"Phase 3 semaglutide CV outcome (SELECT-K)","sponsor":"Novo Nordisk","country":"Korea","drug":"semaglutide","phase":"3","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000011","title":"Phase 2 SGLT2-GLP-1 combo obesity","sponsor":"AstraZeneca","country":"Korea","drug":"dapagliflozin+semaglutide","phase":"2","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000012","title":"Phase 3 sarcopenic obesity exercise+drug","sponsor":"Investigator-Initiated","country":"Korea","drug":"semaglutide","phase":"3","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000013","title":"Phase 2 MASH FGF21 analog","sponsor":"Akero","country":"Korea","drug":"efruxifermin","phase":"2","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000014","title":"Phase 2 MASH PPAR pan-agonist","sponsor":"Inventiva","country":"Korea","drug":"lanifibranor","phase":"2","recruitment_status":"recruiting","sub_investigator_open":true},
  {"nct_id":"NCT06000015","title":"Phase 2 obesity oral GLP-1 next-gen","sponsor":"Lilly","country":"Korea","drug":"orforglipron","phase":"2","recruitment_status":"recruiting","sub_investigator_open":true}
]